Inovio Pharmaceuticals (INO) PT Raised to $24 at Maxim Group, Following $71M DoD Contract
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.64 -1.2%
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy raised the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $24.00 (from $18.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Upgrades Inovio Pharmaceuticals (INO) to Buy
- AMD (AMD) PT Raised to $600 at DA Davidson
- Increasing unusual option volume: USAS INO SHOE BSX CHGG EVGO SGHC REAL MNRO EWT SYF SGI MSOS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
